By Gage Skidmore from Surprise, AZ, United States of America - Robert F. Kennedy, Jr., CC BY-SA 2.0,
For decades, Americans were told a story about their health that no longer matched reality. We were assured that food was safe, that regulators were vigilant, that medical advice was insulated from politics and profit, and that rising chronic disease was an unfortunate but unavoidable byproduct of modern life. Meanwhile, the health of the nation deteriorated in plain sight. Obesity climbed year after year. Childhood chronic disease became common rather than exceptional. Autism rates surged. Cancer diagnoses among children rose. By the time President Trump returned to office, 76.4% of Americans were living with at least one chronic disease. Eight out of 10 children could not qualify for military service. What should have been treated as a civilizational emergency was instead normalized, until that long-running failure of honesty and accountability culminated during the COVID-19 pandemic, when public health leaders abandoned transparency, misled the public, and, under Dr. Fauci’s direction, shattered trust in medical professionals and the institutions meant to serve them.
The collapse of trust that followed COVID did not occur in a vacuum. It was the culmination of years of regulatory capture, scientific arrogance, and a public health establishment that confused authority with truth. Americans were ordered, not persuaded. Dissent was pathologized. Data was selectively presented. Vaccine policy was enforced through mandate rather than transparency. Dr. Fauci became the symbol of an anti-science regime that claimed infallibility while revising its claims in real time. When institutions insist on obedience while refusing accountability, trust does not merely erode; it implodes.
MEASLES: Despite years of unprecedented legal and illegal migration, the US has measles under control compared to peer nations. Canada now has nearly 20X the US case rate, while the UK has roughly triple. Vaccine hesitancy driven by exposed Covid falsehoods is hitting countries… pic.twitter.com/dRfMJrf3J9
It is against this backdrop that the Make America Healthy Again initiative must be understood. MAHA is not a branding exercise or a partisan slogan. It is a course correction. President Trump’s decision to place Robert F. Kennedy Jr. at the helm of HHS was not an appeal to nostalgia or name recognition. It was an explicit rejection of the managerial consensus that presided over the chronic disease explosion. The mandate was simple and radical: identify root causes, dismantle regulatory capture, and tell the truth even when it disrupts powerful interests.
Skeptics ask whether one year can matter. The answer depends on what one expects a first year to do. MAHA was never going to reverse decades of metabolic, environmental, and institutional decay overnight. Its purpose was to reorient the system, establish credibility, and force long-delayed questions back into the open. By that standard, the first year has been historic.
Start with the scope of institutional change. President Trump signed an executive order establishing the MAHA Commission, chaired by Secretary Kennedy, with a singular focus on chronic disease. For the first time in generations, chronic illness was treated not as an actuarial inevitability but as a policy failure demanding investigation. This alone marked a break with orthodoxy. Under previous administrations, chronic disease spending rose to $1.3T annually while prevention remained an afterthought. When Kennedy notes that the federal government once spent essentially nothing on chronic disease, he is not making a rhetorical point. He is diagnosing a structural blind spot.
The results are already visible. Thirty-seven states have enacted legislation advancing MAHA-aligned reforms. Nearly 100 MAHA-related bills have passed nationwide. Eighteen states secured SNAP waivers to restrict taxpayer-funded junk food purchases that directly fuel obesity and diabetes. These are not symbolic victories. They are structural incentives aligned with public health rather than industry convenience.
Food policy has been the most visible arena of reform, and for good reason. The American diet did not become toxic by accident. It was engineered through regulatory loopholes that allowed synthetic additives to enter the food supply under the GRAS standard with minimal oversight. MAHA moved quickly to overhaul this system. Agreements now cover roughly 40% of the food industry, committing to remove petroleum-based synthetic dyes. The dairy industry has pledged to eliminate artificial dyes from ice cream by 2028. These changes matter because they reset norms. Once voluntary reform becomes expected, resistance collapses.
The same logic applies to infant health. Operation Stork Speed was launched to expand access to safe and nutritious infant formula while removing heavy metals that had no business entering baby food in the first place. For parents who watched institutions minimize legitimate safety concerns during COVID, this shift toward precaution and transparency has been decisive in rebuilding trust.
Critics often ask whether MAHA is anti-science. The premise is backward. MAHA is anti-dogma. It insists that science earns authority through openness, replication, and humility. This is why vaccine policy has been reframed around informed consent and gold standard trials rather than mandates. Honesty about uncertainty is not weakness. It is the precondition of credibility. Public trust returns when institutions stop pretending to be omniscient.
This emphasis on trust extends beyond food and vaccines. HHS issued guidance restoring biological truth, recognizing that there are two sexes, male and female. This was not culture war theater. Medicine depends on biological reality. When institutions deny observable facts for ideological reasons, patients notice. Restoring clarity restores confidence.
MAHA’s critics also underestimate the importance of state-level experimentation. Utah’s decision to ban added fluoride in public drinking water did not impose a national mandate. It reopened a conversation that had been closed by bureaucratic inertia. Communities are once again allowed to weigh risks and benefits rather than defer to outdated consensus.
Health care delivery itself has not been ignored. Prior authorization has long functioned as a hidden tax on patients and physicians, delaying care while enriching intermediaries. Secretary Kennedy and CMS Administrator Oz secured industry commitments to streamline this process across health plans. Less paperwork means faster treatment and lower burnout. These are the reforms patients feel immediately.
Drug pricing has followed the same philosophy. President Trump’s most favored nation order is being rapidly implemented to align U.S. prescription drug prices with those paid abroad. This is not price control masquerading as populism. It is a refusal to subsidize global markets at the expense of American patients. Lower prices are a public health intervention.
Physical health has returned to the cultural mainstream as well. The Pete and Bobby Challenge, launched by Secretary Kennedy alongside Defense Secretary Hegseth, did something that countless white papers failed to do. It made fitness visible again. A nation where most children cannot meet basic physical standards is not merely unhealthy. It is vulnerable.
The MAHA Commission’s release of the Make Our Children Healthy Again strategy, outlining more than 120 initiatives, signaled that childhood chronic disease is no longer being treated as a mystery or a taboo. New data linking rising thyroid and kidney cancers among children demands answers. Autism rates demand answers. MAHA has made clear that asking these questions is not forbidden. It is required.
Perhaps the most underestimated achievement of the first year is cultural rather than regulatory. Trust is returning because institutions are speaking plainly. The public understands that special interests once thrived behind closed doors. They know they were sold better cigarettes and sugar smacks with a health halo. What they demanded in 2024 was not perfection. It was honesty.
President Trump and Secretary Kennedy have delivered the first credible attempt in decades to dismantle the alliance between bureaucratic power and corporate profit that hollowed out public health. The appointments at NIH, FDA, and CMS reflect this shift. These are not partisan enforcers. They are reformers tasked with ending capture and restoring the mission.
No serious observer should claim that the work is finished. Chronic disease did not emerge in one year, and it will not be eliminated in one term. But trajectories matter. Incentives matter. Trust matters most of all. After years in which Americans were told to comply and not question, MAHA has reopened the social contract between the public and medicine.
Public health cannot function without consent. Consent requires trust. Trust requires truth. That is the chain MAHA is rebuilding. It is why the first year matters. Not because every problem has been solved, but because the system has finally been pointed in the right direction.
Sponsored by the John Milton Freedom Foundation, a nonprofit dedicated to helping independent journalists overcome formidable challenges in today’s media landscape and bring crucial stories to you.
Gage Skidmore from Surprise, AZ, United States of America, CC BY-SA 2.0 , via Wikimedia Commons
President Donald Trump set off another round of social media speculation Friday after cameras caught what looked like copious amounts of makeup on his hand during public appearances in Washington.
A patch of foundation, slightly lighter than his skin tone, was visible while he toured an exhibit at The People’s House museum. Later that day, during the World Cup 2026 draw event at The Kennedy Center, Trump kept one hand over the other while addressing the crowd — a move that didn’t go unnoticed by outlets like The Daily Beast, which pointed out the recurring appearance of cosmetic cover.
This isn’t the first time similar images have made the rounds. Observers cited previous instances following Trump’s meetings with French President Emmanuel Macron in February, European Commission President Ursula von der Leyen in July, and U.K. Prime Minister Keir Starmer.
Asked about the chatter, White House Press Secretary Karoline Leavitt brushed aside the tabloid-style coverage.
“President Trump is a man of the people, and he meets more Americans and shakes more hands on a daily basis than any other president in history,” Leavitt told The Independent Saturday. “His commitment is unwavering, and he proves that every single day.”
The renewed scrutiny follows last month’s stir over photos showing discoloration and swelling in Trump’s legs during a FIFA Club World Cup appearance. The White House later confirmed the president has chronic venous insufficiency — a common circulatory condition in which blood pools in the veins due to weakened valves.
According to the Cleveland Clinic, the condition can lead to discomfort but is manageable. Leavitt said Trump isn’t in pain and hasn’t required treatment or changes to his daily routine.
In April, White House physician Capt. Sean Barbabella declared the president in “excellent cognitive and physical health” after his annual checkup. He attributed bruising on Trump’s hands to aspirin therapy, a standard precaution for heart health.
FULL TRANSPARENCY: Karoline Leavitt addresses speculation about President Trump’s bruised hand and swollen ankles pic.twitter.com/sKTgb9PYqT
The U.S. Senate has confirmed Robert F. Kennedy Jr. as the next Secretary of Health and Human Services (HHS) following weeks of debate over his nomination.
Once again, Sen. Mitch McConnell (R-Ky.) stood alone as the only Republican to vote against President Trump’s nominee. McConnell opposed Tulsi Gabbard’s nomination as director of national intelligence (DNI).
🚨🚨 BREAKING: The Senate has CONFIRMED Robert F. Kennedy Jr. as secretary of the Department of Health and Human Services.
The confirmation process was marked by intense scrutiny of Kennedy’s record and policy positions. The Senate Finance Committee advanced his nomination last Tuesday with a narrow 14-13 vote.
Senator Bill Cassidy (R-La.), a physician and key swing vote, played a decisive role in moving Kennedy’s nomination forward. Cassidy, who has represented Louisiana in the Senate since 2014, broke with some in his party to support the nominee.
The full Senate advanced Kennedy’s nomination on Wednesday following a successful cloture vote of 53 to 47.
During his confirmation process, Kennedy worked to distance himself from past remarks that raised doubts about vaccine safety.
Despite the controversy, he managed to secure enough backing from Republicans to push his nomination forward.
As head of HHS, Kennedy will oversee federal health policy, including responses to public health crises, health care regulations and medical research funding. His tenure is expected to bring significant policy debates, particularly regarding vaccine policy, regulatory oversight and public health initiatives.
With Kennedy now confirmed, all eyes will be on how he navigates key health policy challenges in the months ahead.
This is a breaking news story. Please check back for updates.
The U.S. Supreme Court on Thursday cleared the way for the Trump administration to move forward with nearly $800 million in cuts to National Institutes of Health grants.
The decision allows the administration to withhold funds that had been frozen by a lower court — grants largely tied to diversity, equity, and inclusion (DEI) initiatives, as well as studies focused on minority health, LGBTQ+ issues, vaccine hesitancy, COVID-19, and similar public health topics.
A federal trial court in Massachusetts had previously ruled in June that many of the cuts were “arbitrary and discriminatory,” ordering the temporary restoration of those grants.
But the Supreme Court, acting through its emergency — or so-called “shadow” — docket, overrode that ruling in a narrow 5–4 decision.
Chief Justice John Roberts sided with the liberal bloc in dissent. Justice Ketanji Brown Jackson issued a sharply worded dissent of her own, criticizing the court’s reliance on the emergency process and the brevity of the majority’s explanation.
As SCOTUSBlogreports, the court — also by a 5–4 margin — left in place another part of the lower court’s ruling affecting internal NIH guidance documents outlining the agency’s policy priorities:
Justice Amy Coney Barrett provided the key vote on each issue. She joined Justices Clarence Thomas, Samuel Alito, Neil Gorsuch, and Brett Kavanaugh in voting to allow NIH to terminate the grants, but she joined Chief Justice John Roberts and Justices Sonia Sotomayor, Elena Kagan, and Ketanji Brown Jackson in voting to leave the lower court’s ruling on the guidance documents in place.
Jackson had sharp words for her colleagues, describing the ruling as “Calvinball jurisprudence” – a reference to the Calvin and Hobbes cartoon – “with a twist. Calvinball has only one rule: There are no fixed rules. We seem to have two: that one, and this Administration always wins.”
Two separate groups of plaintiffs went to federal court in Massachusetts to challenge the termination of the grants. One group is made up of 16 states whose public universities receive funding from NIH, while the other consists of the American Public Health Association, individual researchers, a union, and a reproductive health advocacy group. They contended that the termination of the grants violated both the Constitution and the Administrative Procedure Act, the federal law governing administrative agencies.
The administration argues the research in question lacks scientific rigor and was driven more by ideology than merit. Officials also say the cuts are consistent with their broader push to eliminate DEI-related spending across federal agencies.
Democrat-led states and advocacy groups claim the funding loss could have “incalculable” consequences for underserved communities.
This case fits a broader pattern: The court has recently upheld rollbacks on DEI-based spending in areas like teacher training. Critics say the use of the emergency docket limits public transparency and bypasses full hearings. Supporters say it’s a legitimate tool to keep activist courts in check.
Legal challenges are still moving through the lower courts.
In the meantime, universities, NIH personnel, and left-leaning advocacy groups are mobilizing in protest, warning of long-term damage to public health research and institutional equity efforts.
An adviser to President-elect Trump’s campaign, Alex Bruesewitz, passed out and collapsed as he was speaking onstage during a New York Young Republican Club gala Sunday night.
Alex Bruesewitz, 27, was introducing incoming White House senior aide Dan Scavino inside a venue in Manhattan when he began stumbling over his words and fainted, video on social media shows.
Several people quickly rushed to help after his collapse. It was not immediately clear what caused him to faint.
“I talked to our friend Alex Bruesewitz and you know what he said to me? He goes ‘Did I at least look cool?’ I said Alex, you used gravity like I’ve seen nobody use gravity before in their lives,” Kassam said. “But he’s recuperating back there, so give him a big cheer so he’ll hear you.”
Trump also said following the collapse that he believes Bruesewitz will be fine, according to the New York Post.
“I know that Alex is going to be fine because he’s a tough son of a gun,” Trump said. “There’s no doubt about that. So I want to say hello to Alex, because he’s a very special guy.”
Bruesewitz is the CEO of consultancy firm X Strategies LLC, which states its mission to help elect “America First” candidates. Its website says he is “a prominent political consultant and strategist known for his unwavering support of President Donald Trump and the America First agenda.”
Before his collapse, Bruesewitz commended the New York Republican Club for backing Trump’s campaign. He also gave shout-outs to several supporters of the incoming president who were at the event, including former Florida congressman Matt Gaetz, who recently resigned from his U.S. House seat.
Outgoing Director of National Intelligence Tulsi Gabbard shared an encouraging update Thursday on her husband’s battle with a rare form of bone cancer, revealing that a major surgery to remove the tumor was successful.
Gabbard said her husband, Abraham Williams, recently underwent a nearly seven-hour operation after being diagnosed with sacral chordoma, an extremely rare cancer that forms in the bones of the spine and skull base.
“The surgery to remove bone and surrounding tissue lasted almost seven hours and was successful,” Gabbard wrote in a post on X.
“He had a rough night and is in a lot of pain, but is finally home resting.”
The Trump administration official said the family is now focused on the recovery process.
“Now recovery begins. We’re so grateful for the outpouring of prayers and kind messages from all of you. Our hearts are full,” Gabbard added.
My husband Abraham was diagnosed with a very rare sacral chordoma. The surgery to remove bone and surrounding tissue lasted almost seven hours and was successful. He had a rough night and is in a lot of pain but is finally home resting. Now recovery begins. We’re so grateful…
According to Mayo Clinic research, sacral chordoma is a rare, slow-growing bone cancer that most commonly develops along the spine. While considered slow-growing, the disease can be difficult to treat because of its location, and surgery is often the primary treatment option.
Before the procedure, Gabbard shared a heartfelt message thanking supporters for their prayers.
“We are humbled and so grateful to be surrounded by aloha during this really tough time,” she wrote.
The update comes just weeks after Gabbard announced she would step down from her position in the Trump administration to support her husband through the difficult battle ahead. (RELATED:Tulsi Gabbard Resigning As National Intelligence Director)
“My husband, Abraham, has recently been diagnosed with an extremely rare form of bone cancer,” Gabbard wrote in May. “He faces major challenges in the coming weeks and months. At this time, I must step away from public service to be by his side and fully support him through this battle.”
President Donald Trump praised Gabbard following her resignation announcement, saying she had done “an incredible job” serving in his administration.
Vice President JD Vance also voiced support for the former Hawaii congresswoman.
“I’m sorry to see her go, but certainly understand that family comes first,” Vance said. “She and her husband Abraham will be in my prayers as they face this next challenge together, and she has my gratitude for being a great addition to the administration and a loyal confidante. Godspeed Tulsi!”
Gabbard’s final day in office is expected to be June 30.
The White House has also tapped Federal Housing Finance Agency Director William J. “Bill” Pulte to assume Gabbard’s intelligence role following her departure.
Gabbard, a former Democrat congresswoman from Hawaii, became one of the most prominent political converts of the 2024 election cycle when she endorsed Trump’s presidential campaign and later joined his administration.
The White House, Public domain, via Wikimedia Commons
President Donald Trump has selected Dr. Heidi Overton, a senior White House domestic policy adviser and physician, to lead the Food and Drug Administration as the agency confronts battles over vaccines, drug prices, food additives, and abortion medication.
Trump announced the nomination Wednesday, describing Overton as a trusted problem-solver who would accelerate medical innovation, lower prescription costs, and advance Health and Human Services Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” agenda.
Overton currently serves as deputy director of the White House Domestic Policy Council, where she has helped formulate and promote several of the administration’s most consequential health initiatives.
BREAKING: President Trump picks Dr. Heidi Overton, a top White House aide, to lead the Food and Drug Administration. https://t.co/fGVJ7TNQjt
If confirmed by the Senate, she would succeed Dr. Marty Makary, who left the agency in May after a turbulent tenure marked by internal disputes and disagreements over the direction of federal health policy.
Kyle Diamantas, who previously led the FDA’s Human Foods Program, is serving as acting commissioner.
A Physician With Deep White House Ties
Overton is a board-certified physician in public health and general preventive medicine. She earned her medical degree from the University of New Mexico School of Medicine and a doctorate in clinical investigation from the Johns Hopkins Bloomberg School of Public Health.
She previously trained as a general surgery resident at Johns Hopkins and advocated for greater price and quality transparency in health care.
During medical school, then-New Mexico Gov. Susana Martinez appointed Overton to the University of New Mexico Board of Regents, where she held voting and fiduciary responsibility for the university and its health system.
Overton first entered the Trump White House as a fellow in 2019, working in the Office of American Innovation and on the Domestic Policy Council. Between Trump’s terms, she served as chief policy officer at the America First Policy Institute and helped lead its Center for a Healthy America.
Her biography from the conservative organization emphasizes her work on health-care transparency, fentanyl, public health and policies designed to give patients greater control over medical decisions.
The appointment would place a committed administration loyalist at the head of an agency that regulates products representing roughly one-fifth of American consumer spending.
Overton Helped Shape Trump’s Health Agenda
Overton has appeared alongside Trump during major health policy announcements, including the administration’s efforts to negotiate “most favored nation” agreements with drug companies. The policy seeks to tie American prescription prices to the lower prices paid in other developed countries.
She was also involved in Trump’s controversial effort to revise the childhood vaccination schedule and separate the combined measles, mumps and rubella vaccine into three individual shots.
Major medical organizations have generally supported the combined MMR vaccine, which has been used for decades and reduces the number of clinical visits and injections required for full immunization. Critics fear that splitting the vaccine could create delays and lower vaccination rates.
Overton’s role in the policy is likely to become a focus of her Senate confirmation hearing, particularly as lawmakers question how she would handle pressure from Kennedy and other administration figures skeptical of established federal vaccine recommendations.
Trump praised Overton as a “rockstar” who would advance medical cures, innovation and lower drug prices.
Kennedy also supports the nomination, giving Overton an important ally inside the Department of Health and Human Services, which oversees the FDA.
Difficult Issues Await New Commissioner
The next FDA commissioner will inherit an unusually difficult collection of unfinished projects.
The agency continues to face pressure over its regulation of COVID-19 vaccines and other immunizations, including questions about which populations should receive updated shots and what evidence manufacturers must provide.
Medication abortion will present another immediate test. Pro-life organizations want the FDA to impose tighter restrictions on mifepristone, including limits on prescriptions issued through telehealth and pills delivered through the mail.
Overton has previously used the term “teleabortion” when discussing remote access to abortion medication, drawing concern from abortion-rights organizations that expect her to revisit the drug’s rules.
The FDA must also determine how aggressively it will regulate ultraprocessed foods, chemical additives, and synthetic dyes. Those issues are central to Kennedy’s MAHA movement but can conflict with the deregulatory approach traditionally favored by Republican lawmakers and industry groups.
Other pending questions involve flavored electronic cigarettes, peptide treatments, psychedelics, antidepressant warnings, and efforts to shorten the approval process for new drugs.
Overton would therefore have to balance three competing forces: Trump’s desire for faster approvals and lower prices, Kennedy’s campaign against corporate influence in food and medicine, and Republican demands for reduced federal regulation.
Management Experience Likely to Draw Scrutiny
Overton’s supporters point to her medical education, policy background, and proximity to presidential decision-making. They argue that she understands Trump’s priorities and can coordinate more effectively with the White House than an outside nominee.
Critics are expected to focus on her limited experience running an organization comparable to the FDA.
The agency employs thousands of scientists, physicians, inspectors, lawyers, and regulatory specialists. It oversees prescription drugs, medical devices, vaccines, tobacco products, much of the nation’s food supply, and other consumer goods.
Axios reported before her selection that some health policy observers worried Overton’s nomination could unsettle FDA career employees and pharmaceutical investors, while other potential candidates possessed more direct executive management experience.
The criticism will likely feature prominently when she appears before the Senate Health, Education, Labor and Pensions Committee.
Makary, Overton’s predecessor and a former Johns Hopkins colleague, was confirmed in March 2025 by a 56-44 Senate vote. Overton will seek confirmation from a chamber still controlled by Republicans but divided over the administration’s vaccine policies.
Her nomination signals that Trump wants the FDA led by someone already embedded in his White House rather than an agency insider or pharmaceutical executive.
If the Senate agrees, Overton will take control of one of the federal government’s most powerful scientific agencies — and become responsible for turning the administration’s sprawling health agenda into enforceable policy.
Vanessa Trump is moving forward with optimism as she continues her battle with breast cancer.
The former wife of Donald Trump Jr. shared a heartfelt update with supporters Saturday, revealing that she has spent the past several weeks recovering from surgery and is preparing to begin the next phase of her treatment.
“I wanted to share an update on my cancer journey,” Trump wrote in an Instagram post. “Over the past four weeks, I’ve been recovering from surgery and I’m grateful to be healing and moving forward. Soon, I’ll be starting the second stage of my treatment. Sending love, strength, and hope to everyone fighting this battle.”
Vanessa first revealed her diagnosis publicly on May 20, telling followers that she was focused on her health and recovery while surrounded by loved ones. At the time, she briefly referenced an upcoming medical procedure but chose not to disclose many details about her treatment plan.
In Saturday’s update, Trump did not elaborate on the surgery or the next stage of treatment. Instead, she emphasized gratitude and the support system helping her through the difficult journey.
“I am staying focused and hopeful while surrounded by the love and support of my family, my kids, and those closest to me,” she previously wrote, adding, “I kindly ask for privacy as I focus on my health and recovery.”
The update prompted an outpouring of support from friends, family members, and followers. Ivanka Trump publicly shared her encouragement, writing, “Praying for your continued strength and a swift recovery. Love you mama.”
Vanessa and Donald Trump Jr. were married for more than a decade and share five children together: Kai, Donald III, Tristan, Spencer, and Chloe. Though the couple divorced in 2018, they have remained committed co-parents, frequently appearing together at family milestones and supporting their children’s activities.
The latest health update comes during a busy season for the extended Trump family. Just weeks ago, Donald Trump Jr. married Bettina Anderson during a ceremony in the Bahamas over Memorial Day weekend, bringing together family and friends for the celebration.
Meanwhile, Vanessa’s relationship with golf icon Tiger Woods has also drawn public attention in recent months. The pair have largely kept their romance private, though reports have suggested Woods has remained supportive as Vanessa navigates treatment and recovery.
For now, Vanessa appears focused on her health, her family, and the road ahead — while continuing to receive support from those closest to her as she begins the next chapter of treatment.
Gage Skidmore from Surprise, AZ, United States of America, CC BY-SA 2.0 , via Wikimedia Commons
Minnesota Senate Republicans have introduced a bill to define “Trump Derangement Syndrome” (TDS) as a form of mental illness. Senate Bill 2589, which is set to be formally introduced and read on March 17, 2025, igniting significant debate due to the novelty of a politically charged term in the medical lexicon.
The bill, sponsored by Republican State Senators Eric Lucero, Steve Drazkowski, Nathan Wesenberg, Justin Eichorn, and Glenn Gruenhagen, seeks to amend the state’s definition of mental illness by adding a specific reference to TDS. According to the text of the bill, mental illness would include “Trump Derangement Syndrome” or an organic disorder of the brain that significantly impairs an individual’s ability to function in daily life.
The bill describes TDS as “the acute onset of paranoia in otherwise normal persons that is in reaction to the policies and presidencies of President Donald J. Trump.” According to the proposal, individuals affected by TDS exhibit symptoms of paranoia and an inability to separate legitimate political disagreements from perceived personal or psychological pathology in Trump’s behavior.
The bill further characterizes TDS as leading to “Trump-induced general hysteria,” where individuals may struggle to distinguish between policy differences and a supposed mental condition in the former president’s actions. These symptoms, the bill argues, can severely impair personal relationships, work, and other aspects of daily living.
The bill has already been logged into the Minnesota legislature’s official website, but it is set to undergo formal introduction on March 17, 2025. Its introduction has garnered widespread attention, with reactions split along party lines.
Supporters of the bill argue that it is a legitimate attempt to address a condition that they believe affects a significant portion of the population, particularly those who strongly opposed former President Trump. By naming and defining TDS, they argue, the bill opens a discussion about how political figures can profoundly affect the psychological well-being of individuals, especially during times of heightened political polarization.
Article Published With The Permission of American Liberty News
Fox News anchor John Roberts has revealed he’s been hospitalized after contracting what he described as a “severe case of malaria,” sidelining him from his weekday slot on America Reports.
“I somehow came down with a severe case of malaria,” Roberts, 68, announced via X on Tuesday. “I can honestly say that I am the only person in the hospital with malaria. In fact, one of my doctors said I’m the first case he has ever seen.”
Thank you to Trace for jumping into the chair today! I somehow came down with a severe case of Malaria. I can honestly say that I am the only person in the hospital with Malaria. In fact, one of my doctors said I’m the first case he has ever seen. Thanks to the folks at… https://t.co/6ZHiB5Dv8v
Malaria was eliminated from the U.S. in 1951, according to the CDC. However, the country still sees about 2,000 malaria cases per year. There were, on average, nearly seven deaths per year between 2007 and 2022.
Malaria cases in the U.S. are now mostly linked to international travel.
Malaria is spread by mosquitoes. Cases in the U.S. were typically in people who traveled to or from countries where the disease is widespread. The CDC said locally acquired, mosquito-transmitted malaria is “rare” in the country.
Malaria patients often reported having recently returned from Africa, the CDC said. Patients commonly reported visiting friends and family as their primary reason for travel.
MAHA Year One: How Trump & RFK Jr. Are Rebuilding American Health
For decades, Americans were told a story about their health that no longer matched reality. We were assured that food was safe, that regulators were vigilant, that medical advice was insulated from politics and profit, and that rising chronic disease was an unfortunate but unavoidable byproduct of modern life. Meanwhile, the health of the nation deteriorated in plain sight. Obesity climbed year after year. Childhood chronic disease became common rather than exceptional. Autism rates surged. Cancer diagnoses among children rose. By the time President Trump returned to office, 76.4% of Americans were living with at least one chronic disease. Eight out of 10 children could not qualify for military service. What should have been treated as a civilizational emergency was instead normalized, until that long-running failure of honesty and accountability culminated during the COVID-19 pandemic, when public health leaders abandoned transparency, misled the public, and, under Dr. Fauci’s direction, shattered trust in medical professionals and the institutions meant to serve them.
The collapse of trust that followed COVID did not occur in a vacuum. It was the culmination of years of regulatory capture, scientific arrogance, and a public health establishment that confused authority with truth. Americans were ordered, not persuaded. Dissent was pathologized. Data was selectively presented. Vaccine policy was enforced through mandate rather than transparency. Dr. Fauci became the symbol of an anti-science regime that claimed infallibility while revising its claims in real time. When institutions insist on obedience while refusing accountability, trust does not merely erode; it implodes.
It is against this backdrop that the Make America Healthy Again initiative must be understood. MAHA is not a branding exercise or a partisan slogan. It is a course correction. President Trump’s decision to place Robert F. Kennedy Jr. at the helm of HHS was not an appeal to nostalgia or name recognition. It was an explicit rejection of the managerial consensus that presided over the chronic disease explosion. The mandate was simple and radical: identify root causes, dismantle regulatory capture, and tell the truth even when it disrupts powerful interests.
Skeptics ask whether one year can matter. The answer depends on what one expects a first year to do. MAHA was never going to reverse decades of metabolic, environmental, and institutional decay overnight. Its purpose was to reorient the system, establish credibility, and force long-delayed questions back into the open. By that standard, the first year has been historic.
Start with the scope of institutional change. President Trump signed an executive order establishing the MAHA Commission, chaired by Secretary Kennedy, with a singular focus on chronic disease. For the first time in generations, chronic illness was treated not as an actuarial inevitability but as a policy failure demanding investigation. This alone marked a break with orthodoxy. Under previous administrations, chronic disease spending rose to $1.3T annually while prevention remained an afterthought. When Kennedy notes that the federal government once spent essentially nothing on chronic disease, he is not making a rhetorical point. He is diagnosing a structural blind spot.
The results are already visible. Thirty-seven states have enacted legislation advancing MAHA-aligned reforms. Nearly 100 MAHA-related bills have passed nationwide. Eighteen states secured SNAP waivers to restrict taxpayer-funded junk food purchases that directly fuel obesity and diabetes. These are not symbolic victories. They are structural incentives aligned with public health rather than industry convenience.
Food policy has been the most visible arena of reform, and for good reason. The American diet did not become toxic by accident. It was engineered through regulatory loopholes that allowed synthetic additives to enter the food supply under the GRAS standard with minimal oversight. MAHA moved quickly to overhaul this system. Agreements now cover roughly 40% of the food industry, committing to remove petroleum-based synthetic dyes. The dairy industry has pledged to eliminate artificial dyes from ice cream by 2028. These changes matter because they reset norms. Once voluntary reform becomes expected, resistance collapses.
The same logic applies to infant health. Operation Stork Speed was launched to expand access to safe and nutritious infant formula while removing heavy metals that had no business entering baby food in the first place. For parents who watched institutions minimize legitimate safety concerns during COVID, this shift toward precaution and transparency has been decisive in rebuilding trust.
Critics often ask whether MAHA is anti-science. The premise is backward. MAHA is anti-dogma. It insists that science earns authority through openness, replication, and humility. This is why vaccine policy has been reframed around informed consent and gold standard trials rather than mandates. Honesty about uncertainty is not weakness. It is the precondition of credibility. Public trust returns when institutions stop pretending to be omniscient.
This emphasis on trust extends beyond food and vaccines. HHS issued guidance restoring biological truth, recognizing that there are two sexes, male and female. This was not culture war theater. Medicine depends on biological reality. When institutions deny observable facts for ideological reasons, patients notice. Restoring clarity restores confidence.
MAHA’s critics also underestimate the importance of state-level experimentation. Utah’s decision to ban added fluoride in public drinking water did not impose a national mandate. It reopened a conversation that had been closed by bureaucratic inertia. Communities are once again allowed to weigh risks and benefits rather than defer to outdated consensus.
Health care delivery itself has not been ignored. Prior authorization has long functioned as a hidden tax on patients and physicians, delaying care while enriching intermediaries. Secretary Kennedy and CMS Administrator Oz secured industry commitments to streamline this process across health plans. Less paperwork means faster treatment and lower burnout. These are the reforms patients feel immediately.
Drug pricing has followed the same philosophy. President Trump’s most favored nation order is being rapidly implemented to align U.S. prescription drug prices with those paid abroad. This is not price control masquerading as populism. It is a refusal to subsidize global markets at the expense of American patients. Lower prices are a public health intervention.
Physical health has returned to the cultural mainstream as well. The Pete and Bobby Challenge, launched by Secretary Kennedy alongside Defense Secretary Hegseth, did something that countless white papers failed to do. It made fitness visible again. A nation where most children cannot meet basic physical standards is not merely unhealthy. It is vulnerable.
The MAHA Commission’s release of the Make Our Children Healthy Again strategy, outlining more than 120 initiatives, signaled that childhood chronic disease is no longer being treated as a mystery or a taboo. New data linking rising thyroid and kidney cancers among children demands answers. Autism rates demand answers. MAHA has made clear that asking these questions is not forbidden. It is required.
Perhaps the most underestimated achievement of the first year is cultural rather than regulatory. Trust is returning because institutions are speaking plainly. The public understands that special interests once thrived behind closed doors. They know they were sold better cigarettes and sugar smacks with a health halo. What they demanded in 2024 was not perfection. It was honesty.
President Trump and Secretary Kennedy have delivered the first credible attempt in decades to dismantle the alliance between bureaucratic power and corporate profit that hollowed out public health. The appointments at NIH, FDA, and CMS reflect this shift. These are not partisan enforcers. They are reformers tasked with ending capture and restoring the mission.
No serious observer should claim that the work is finished. Chronic disease did not emerge in one year, and it will not be eliminated in one term. But trajectories matter. Incentives matter. Trust matters most of all. After years in which Americans were told to comply and not question, MAHA has reopened the social contract between the public and medicine.
Public health cannot function without consent. Consent requires trust. Trust requires truth. That is the chain MAHA is rebuilding. It is why the first year matters. Not because every problem has been solved, but because the system has finally been pointed in the right direction.
If you enjoy my work, please subscribe: https://x.com/amuse.
Sponsored by the John Milton Freedom Foundation, a nonprofit dedicated to helping independent journalists overcome formidable challenges in today’s media landscape and bring crucial stories to you.
Sponsored
Arizona is at risk — and Turning Point needs you NOW. Your donation funds ballot chasers and wins critical state races. Donate TODAY to help save America — one state at a time.